Co­manche lines up tri­al for preeclamp­sia siR­NA with Mod­er­na, Med­i­cines Com­pa­ny vets and GV back­ing

A new siR­NA biotech from Mod­er­na and Med­i­cines Com­pa­ny vet­er­ans is near­ing the clin­ic as it looks to ad­dress ris­ing ma­ter­nal health risks and re­duce a life-threat­en­ing com­pli­ca­tion in preg­nan­cies that im­pacts mil­lions of women like Allyson Fe­lix, Amer­i­ca’s most-dec­o­rat­ed track Olympian.

The start­up, Co­manche Bio­phar­ma, has been op­er­at­ing most­ly in stealth mode un­til this point, and is de­vel­op­ing a one-time ther­a­py that it hopes will work for about 90% of preeclamp­sia cas­es, said chief med­ical of­fi­cer Al­li­son Au­gust, a for­mer VP of clin­i­cal de­vel­op­ment for in­fec­tious dis­eases at Mod­er­na. Fe­lix was al­so re­cent­ly named a board mem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER